Text Size

A A A

Search


 

Home | Clinical Trials

FDA Approved Drugs » 1997
Medical Areas: Neurology | Pharmacology/Toxicology | Hepatology (Liver, Pancreatic, Gall Bladder) | Genetic Disease

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

Galzin (zinc acetate)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Teva Pharmaceutical
Approval Status: Approved January 1997
Treatment Area: Wilson’s disease

General Information

Galzin has been approved for the treatment of Wilson's disease. Wilson’s disease is a potentially fatal inherited abnormality, occurring in one of 30,000 people, that causes excess copper to accumulate in the body, affecting the liver and the brain. Patients become ill as teenagers or as young adults with liver disease, often with neurologic symptoms. Galzin works by blocking absorption of copper from the intestine.


 Back to Top | Printer Friendly Version

Get Involved

Stroke and You

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

National Stroke Association

1-800-STROKES
1-800-787-6537
9707 E. Easter Lane, Suite B
Centennial, CO 80112
info@stroke.org